BioSpace News Archive

ConcertAI, LLC today announced the appointment of Claudio D’Ambrosio, PhD, as its first Chief Revenue Officer.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and announced strategic objectives and expected milestones for 2023.

Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations.

atai Life Sciences announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience’s Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression.

Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the opening of Bioworks7, the latest expansion of its biological engineering foundry.

Aeglea BioTherapeutics today announced an update to its corporate structure.

Baxter International Inc. announced a comprehensive strategic roadmap to meaningfully enhance its operational effectiveness, drive toward improved long-term performance, accelerate innovation and create additional value for all stakeholders.

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference.

AssayQuant Technologies, Inc announced today that it is presenting at Biotech Showcase™ 2023.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete responses in a total of 6 relapsed/refractory AL amyloidosis patients.